337 related articles for article (PubMed ID: 17216565)
1. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Waldmann TA
J Clin Immunol; 2007 Jan; 27(1):1-18. PubMed ID: 17216565
[TBL] [Abstract][Full Text] [Related]
2. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.
Waldmann TA
Oncogene; 2007 May; 26(25):3699-703. PubMed ID: 17530023
[TBL] [Abstract][Full Text] [Related]
3. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on anti-CD25: daclizumab in MS.
Schippling DS; Martin R
Int MS J; 2008 Sep; 15(3):94-8. PubMed ID: 18808743
[TBL] [Abstract][Full Text] [Related]
5. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis.
Martin R
Neurodegener Dis; 2008; 5(1):23-6. PubMed ID: 18075271
[TBL] [Abstract][Full Text] [Related]
6. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.
Chen J; Zhang M; Ju W; Waldmann TA
Blood; 2009 Feb; 113(6):1287-93. PubMed ID: 18948574
[TBL] [Abstract][Full Text] [Related]
7. The interleukin-2 inhibitors and their role in low-toxicity regimens.
Nashan B
Transplant Proc; 1999 Dec; 31(8A):23S-26S. PubMed ID: 10616557
[No Abstract] [Full Text] [Related]
8. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
Nussenblatt RB; Thompson DJ; Li Z; Chan CC; Peterson JS; Robinson RR; Shames RS; Nagarajan S; Tang MT; Mailman M; Velez G; Roy C; Levy-Clarke GA; Suhler EB; Djalilian A; Sen HN; Al-Khatib S; Ursea R; Srivastava S; Bamji A; Mellow S; Sran P; Waldmann TA; Buggage RR
J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854
[TBL] [Abstract][Full Text] [Related]
9. Daclizumab: a potential asthma therapy?
Antoniu SA
Recent Pat Inflamm Allergy Drug Discov; 2010 Nov; 4(3):214-21. PubMed ID: 20804450
[TBL] [Abstract][Full Text] [Related]
10. Daclizumab.
Mottershead M; Neuberger J
Expert Opin Biol Ther; 2007 Oct; 7(10):1583-96. PubMed ID: 17916050
[TBL] [Abstract][Full Text] [Related]
11. The use of antibodies against the IL-2 receptor in transplantation.
Waldmann TA; O'Shea J
Curr Opin Immunol; 1998 Oct; 10(5):507-12. PubMed ID: 9794841
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
[TBL] [Abstract][Full Text] [Related]
13. Clinical advances in therapies targeting the interleukin-2 receptor.
Church AC
QJM; 2003 Feb; 96(2):91-102. PubMed ID: 12589007
[No Abstract] [Full Text] [Related]
14. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group.
Hengster P; Pescovitz MD; Hyatt D; Margreiter R
Transplantation; 1999 Jul; 68(2):310-3. PubMed ID: 10440409
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.
Berkowitz JL; Janik JE; Stewart DM; Jaffe ES; Stetler-Stevenson M; Shih JH; Fleisher TA; Turner M; Urquhart NE; Wharfe GH; Figg WD; Peer CJ; Goldman CK; Waldmann TA; Morris JC
Clin Immunol; 2014 Dec; 155(2):176-87. PubMed ID: 25267440
[TBL] [Abstract][Full Text] [Related]
16. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis.
Krueger JG; Walters IB; Miyazawa M; Gilleaudeau P; Hakimi J; Light S; Sherr A; Gottlieb AB
J Am Acad Dermatol; 2000 Sep; 43(3):448-58. PubMed ID: 10954656
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.
Koch M; Niemeyer G; Patel I; Light S; Nashan B
Transplantation; 2002 May; 73(10):1640-6. PubMed ID: 12042653
[TBL] [Abstract][Full Text] [Related]
18. Daclizumab: a review of its use in the management of organ transplantation.
Carswell CI; Plosker GL; Wagstaff AJ
BioDrugs; 2001; 15(11):745-73. PubMed ID: 11707149
[TBL] [Abstract][Full Text] [Related]
19. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
Pascual J; Marcén R; Ortuño J
Nephrol Dial Transplant; 2001 Sep; 16(9):1756-60. PubMed ID: 11522853
[No Abstract] [Full Text] [Related]
20. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.
Beniaminovitz A; Itescu S; Lietz K; Donovan M; Burke EM; Groff BD; Edwards N; Mancini DM
N Engl J Med; 2000 Mar; 342(9):613-9. PubMed ID: 10699160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
